-
11.发明授权公开(公告)号：US09982051B2
公开(公告)日：2018-05-29
申请号：US15821678
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K31/7068 , A61K38/00 , A61K38/18 , A61K38/16 , A61K38/02 , A61K45/06 , A61K31/4155 , A61K38/14 , A61K38/20 , A61K33/36 , A61K31/404 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
12.发明授权公开(公告)号：US09982050B2
公开(公告)日：2018-05-29
申请号：US15821672
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K38/16 , A61K31/7068 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K38/20 , A61K33/36 , A61K31/404 , A61K31/4155 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
13.发明授权公开(公告)号：US09982048B2
公开(公告)日：2018-05-29
申请号：US15821595
申请日：2017-11-22
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K38/16 , A61K31/7068 , A61K45/06 , A61K38/18 , A61K38/14 , A61K38/00 , A61K38/20 , A61K33/36 , A61K31/404 , A61K31/4155 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
14.发明授权公开(公告)号：US09856318B2
公开(公告)日：2018-01-02
申请号：US14797894
申请日：2015-07-13
Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K38/00 , A61K31/4155 , A61K38/16 , A61K38/18 , A61K38/20 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K16/2818 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.
-
15.发明申请Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS 审中-公开减少系统性调节性T细胞水平或治疗CNS疾病和损伤的活动公开(公告)号：US20170029508A1
公开(公告)日：2017-02-02
申请号：US15261945
申请日：2016-09-10
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
Abstract translation: 本说明书公开了一种药物组合物，其包含活性剂，其导致个体中降低全身免疫抑制水平用于治疗CNS的疾病，病症，病状或损伤。 药物组合物通过包含至少一疗程疗程的给药方案施用，每个治疗过程依次包括治疗会话，然后是间歇疗程的非治疗。
-
Patent Agency Ranking
公开(公告)号：US09382293B2
公开(公告)日：2016-07-05
申请号：US14384685
申请日：2013-03-14
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Matityahu Fridkin , Michal Cardon-Yaakov
CPC classification number: C07K7/06 , A61K9/0053 , A61K38/00 , C07K7/64
Abstract: The present application provides synthetic modified peptides of five to seven natural or non-natural amino acids as well as pharmaceutical compositions comprising them, for use in the treatment a disease or disorder presenting behavioral abnormalities associated with impairment of sensory gating function, depression or cognitive impairment, particularly schizophrenia and Alzheimer's disease.
Abstract translation: 本申请提供五至七个天然或非天然氨基酸的合成修饰肽以及包含它们的药物组合物，用于治疗与感觉门控功能障碍，抑郁症或认知障碍相关的行为异常的疾病或病症 ，特别是精神分裂症和阿尔茨海默病。
-
17.发明公开公开(公告)号：US20240182566A1
公开(公告)日：2024-06-06
申请号：US18535960
申请日：2023-12-11
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/02 , A61K38/14 , A61K38/16 , A61K38/18 , A61K38/20 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/39541 , A61K39/3955 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
18.发明授权公开(公告)号：US11884728B2
公开(公告)日：2024-01-30
申请号：US17187011
申请日：2021-02-26
Applicant: Yeda Research and Development Co. Ltd.
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61P37/02 , A61P25/28 , A61K38/00 , A61K38/14 , A61K45/06 , A61K31/404 , A61K31/7068 , A61K33/36 , A61K38/16 , A61K38/18 , A61K38/20 , A61K31/4155 , A61K38/02 , A61K39/00
CPC classification number: C07K16/2803 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K38/00 , A61K38/005 , A61K38/02 , A61K38/14 , A61K38/168 , A61K38/18 , A61K38/208 , A61K39/395 , A61K39/3955 , A61K39/39541 , A61K45/06 , C07K16/2818 , C07K16/2827 , A61K2039/505 , A61K2039/507 , A61K2039/545 , A61K2039/57 , A61K2039/572 , A61K2121/00 , C07K2317/21 , C07K2317/24 , C07K2317/75 , C07K2317/76 , A61K38/208 , A61K2300/00 , A61K33/36 , A61K2300/00 , A61K31/404 , A61K2300/00 , A61K31/4155 , A61K2300/00 , A61K31/7068 , A61K2300/00
Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
19.发明授权公开(公告)号：US10519237B2
公开(公告)日：2019-12-31
申请号：US15261945
申请日：2016-09-10
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Kuti Baruch , Neta Rosenzweig
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K31/404 , A61K31/4155 , A61K31/7068 , A61K33/36 , A61K39/00
Abstract: The present specification discloses a pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS. The pharmaceutical composition is administered by a dosage regimen comprising at least one course of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session of non-treatment.
-
公开(公告)号：US10188679B2
公开(公告)日：2019-01-29
申请号：US14898732
申请日：2014-05-22
Applicant: Yeda Research and Development Co. Ltd
Inventor： Michal Eisenbach-Schwartz , Ester Yoles , Inbal Benhar Bar-On
Abstract: A monocyte subpopulation having a low relative amount, or substantially devoid, of CD3+ cells, CD19+ cells, CD56+ cells and optionally CD16+ cells is provided, wherein the monocyte subpopulation is for use in inhibition of neuronal degeneration, protection of neurons from glutamate toxicity or promotion of nerve regeneration in the retina or optic nerve, wherein the retina or optic nerve is damaged by a disease, disorder or condition of the eye, or for treatment of an inflammatory disease, disorder or condition of the eye.
-
-
-
-
-
-
-
-
-
Search Results
52
records
(took 0.031 seconds)
